Effects of vitamin E-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis

Abstract

HD with the use of VEM resulted in a significant reduction in inflammation and oxidative stress markers. Larger prospective randomized studies will need to confirm the findings of the present observational study.

Effects of vitamin E-coated dialysis membranes on anemia, nutrition and dyslipidemia status in hemodialysis patients: a meta-analysis

“…1,24,26 The meta-analysis showed that there was no statistically significant change in serum cholesterol in the vitamin E-coated dialyzer groups (SMD, À0.07; 95% CI, À0.45 to 0.31; p ¼ 0.71), with minimal heterogeneity (p ¼ 0.46; I 2 ¼ 0%). The changes in serum triglycerides fractions were analyzed from two trials.…”

“…Among them, duplicate records, non-RCTs or quasi-RCTs, review and letter, article not in English, other intervention and concerning other outcome were excluded. After the progressive selection process, 14 eligibility studies 1,8,[13][14][15][16][21][22][23][24][25][26][27][28] including five crossover and nine parallel-arm trials were included in this meta-analysis ( Figure 1). …”

“…Incomplete outcome data: Four studies reported withdrawals, 15,16,22,24 but the results were not analyzed on an intention-to-treat basis. Ten trials were assessed to be low risk of attrition bias.…”

“…14,21,23,24 When the metaanalysis was performed, no significant effect was found after conversion from conventional dialyzer to vitamin E-coated dialyzer (SMD, À0.64; 95% CI, À1.62 to 0.34; p ¼ 0.2), with evidence of heterogeneity (p ¼ 0.004; I 2 ¼ 78%).…”

Review of the Effectiveness of Cellulose- and Polysulfone-Based Vitamin E-Bonded Dialysis Membranes

“…Other reports demonstrated positive effects such as (1) decreased oxidative stress (Tarng et al, 2000;Miyazaki et al, 2000;Clermont et al, 2001;Westhuyzen et al, 2003;Bufano et al, 2004;Mydlik et al, 2004;Calò et al, 2004;Yang et al, 2006;and Odetti et al, 2006), (2) suppression of leukocyte activation (Omata et al, 2000;Zaluska et al, 2001;Pertosa et al, 2002;Tsuruoka et al, 2002;Libetta et al, 2004;and Kojima et al, 2005), (3) dosage reduction of anticoagulants (Huraib et al, 2000), (4) improved biocompatibility (Yoshida et al, 2002), and (5) decreased levels of advanced glycation end products (AGEs) (Baragetti et al, 2006). Moreover, a recent study reported by Kirmizis D et al, 2010, showed that the levels of inflammatory markers such as C-reactive protein (CRP), interleukin (IL)-6, and soluble intercellular adhesion molecule (sICAM)-1 in 35 patients treated with Excebrane were lower than those in the baseline evaluation carried out with conventional low-or middle-flux dialyzers. Whereas, no change was observed throughout the experimental period in a matched control group of 25 patients who underwent treatment with the unmodified dialyzers.…”